DR. MARK PIMENTEL, M.D.
Osteopathic Medicine in Los Angeles, CA
License number
California A60576
Category
Osteopathic Medicine
Type
Gastroenterology
Address
Address
8700 Beverly Blvd., Los Angeles, CA 90048
Phone
(310) 423-6143
(310) 423-8356 (Fax)
(310) 423-8356 (Fax)
Personal information
See more information about MARK PIMENTEL at radaris.comName
Address
Phone
5093 Tifton Way, San Jose, CA 95118
9805 Burgen Ave, Los Angeles, CA 90034
8919 Cielito St, Rch Cucamonga, CA 91701
8227 Calle Morelos, San Diego, CA 92126
698 Royal Arch Ct, Merced, CA 95340
Organization information
See more information about MARK PIMENTEL at bizstanding.comMark Pimentel MD
8730 Gracie Allen Dr, Los Angeles, CA 90048
Industry:
Gastroenterology, Internist
Phone:
(310) 423-6143 (Phone)
Mark Pimentel
Cedars Sinai Medical Center - Mark Pimentel MD
8700 Beverly Blvd #2E, West Hollywood, CA 90048
Categories:
Gastroenterology Physicians & Surgeons
Phone:
(310) 423-6143 (Phone)
Professional information
Dr. Mark Pimentel, Los Angeles CA - MD (Doctor of Medicine)
Address:
Los Angeles Office
8730 Gracie Allen Dr SUITE E-216, Los Angeles 90048
(310) 967-1884 (Phone)
Los Angeles Office
8730 Gracie Allen Dr SUITE E-216, Los Angeles 90048
(310) 967-1884 (Phone)
8730 Gracie Allen Dr SUITE E-216, Los Angeles 90048
(310) 967-1884 (Phone)
Los Angeles Office
8730 Gracie Allen Dr SUITE E-216, Los Angeles 90048
(310) 967-1884 (Phone)
Education:
Medical Schools
UNIVERSITY OF MANITOBA / FACULTY OF MEDICINE
UNIVERSITY OF MANITOBA / FACULTY OF MEDICINE
Method Of Using A Probiotic Agent For The Treatment Of Diarrhea
US Patent:
2008013, Jun 12, 2008
Filed:
Feb 13, 2008
Appl. No.:
12/030758
Inventors:
Mark Pimentel - Los Angeles CA, US
Henry C. Lin - Albuquerque NM, US
Henry C. Lin - Albuquerque NM, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
A61K 35/74
US Classification:
424 934
Abstract:
Disclosed is a method of manipulating the rate of gastrointestinal transit in a mammalian subject. Also disclosed is the use, in the manufacture of a medicament for the treatment of constipation, of a selective inhibitor of methanogensis, a methanogen-displacing probiotic agent, or a prebiotic agent that inhibits the growth of methanogenic bacteria or promotes the growth of competing non-methanogenic intestinal flora. Alternatively, in accordance with the invention, is disclosed the use in the manufacture of a medicament for the treatment of diarrhea, of methane or a methane precursor, a methanogenic or other methane-enhancing probiotic agent, or a methanogenesis-enhancing prebiotic agent.
Mark Pimentel, West Hollywood CA
Specialties:
Internal Medicine, Gastroenterology
Work:
Cedars-Sinai Medical Center
8700 Beverly Blvd, Los Angeles, CA 90048 Cedars-Sinai Medical Center
8635 W 3Rd St, Los Angeles, CA 90095 Cedars-Sinai Medical Center
8730 Alden Dr, Los Angeles, CA 90048
8700 Beverly Blvd, Los Angeles, CA 90048 Cedars-Sinai Medical Center
8635 W 3Rd St, Los Angeles, CA 90095 Cedars-Sinai Medical Center
8730 Alden Dr, Los Angeles, CA 90048
Education:
University Of Manitoba Faculty Of Medicine (1992)
Methods Of Diagnosing Irritable Bowel Syndrome And Other Disorders Caused By Small Intestinal Bacterial Overgrowth
US Patent:
6805852, Oct 19, 2004
Filed:
Mar 26, 2002
Appl. No.:
10/107240
Inventors:
Henry C. Lin - Manhattan Beach CA
Mark Pimentel - Los Angeles CA
Mark Pimentel - Los Angeles CA
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
International Classification:
A61K 5100
US Classification:
424 111, 424 91, 435 4, 435 772, 435 34
Abstract:
Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohns disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis of any of those diagnostic categories. Also disclosed is a method of treating these disorders, and other disorders caused by SIBO, that involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of anti-microbial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. The method improves symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO. Also disclosed is a kit for the diagnosis or treatment of irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, or Crohns disease.
Method Of Diagnosing Irritable Bowel Syndrome And Other Disorders Caused By Small Intestinal Bacterial Overgrowth By Detecting The Presence Of Anti-Saccharomyces Cerivisiae Antibodies (Asca) In Human Serum
US Patent:
6562629, May 13, 2003
Filed:
Aug 11, 1999
Appl. No.:
09/374143
Inventors:
Henry C. Lin - Manhattan Beach CA
Mark Pimentel - Los Angeles CA
Mark Pimentel - Los Angeles CA
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
International Classification:
G01N 33564
US Classification:
436506, 435 4, 435 71
Abstract:
Disclosed is a method of diagnosing small intestinal bacterial overgrowth (SIBO), irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder (ADHD), or an autoimmune disease by sampling serum from a human subject having a suspected diagnosis of any of these conditions and analyzing the serum for the presence of ASCA, which corroborates the suspected diagnosis. A method of determining a predisposition for developing Crohns, in a human subject who does not present a set of symptoms characteristic of the disease and who has small intestinal bacterial overgrowth, involves sampling serum from the subject and analyzing the serum for the presence of ASCA. The presence of ASCA in the serum indicates a predisposition for developing Crohns disease. Also disclosed is a kit for diagnosing and treating small intestinal bacterial overgrowth, irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, or an autoimmune disease, such as multiple sclerosis or systemic lupus erythematosus.
Methods Of Treating Diarrhea And Bloating Caused By Small Intestinal Bacterial Overgrowth
US Patent:
7605240, Oct 20, 2009
Filed:
Aug 14, 2007
Appl. No.:
11/838672
Inventors:
Henry C. Lin - Albuquerque NM, US
Mark Pimentel - Los Angeles CA, US
Mark Pimentel - Los Angeles CA, US
Assignee:
Cedara-Sinai Medical Center - Los Angeles CA
International Classification:
C07G 11/00
US Classification:
536 168
Abstract:
Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis of any of those diagnostic categories. Also disclosed is a method of treating these disorders, and other disorders caused by SIBO, that involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of anti-microbial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. The method improves symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO. Also disclosed is a kit for the diagnosis or treatment of irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, or Crohn's disease.
Manipulation Of The Rate Of Gastrointestinal Transit By Modulating Intestinal Methane Concertration
US Patent:
2006024, Nov 2, 2006
Filed:
May 20, 2003
Appl. No.:
10/514188
Inventors:
Mark Pimentel - Los Angeles CA, US
Henry Lin - Los Angeles CA, US
Henry Lin - Los Angeles CA, US
International Classification:
A61K 35/74, A61K 31/405
US Classification:
424093450, 514419000
Abstract:
Disclosed is a method of manipulating the rate of gastrointestinal transit in a mammalian subject Also disclosed is the use, in the manufacture of a medicamens for the treatment of constipation, of a selective inhibitor of methanogensis, a methanogen-displacing probiotic agent, or a prebiotic agent that inhibits the growth of methanogenic bacteria or promotes the growth of competing non-methanogenic intestinal flora. Alternatively, in accordance with the invention, is disclosed the use in the manufacture of a medicament for the treatment of diarrhea, of methane, or a methane precursor, a methanogenic or other methane-enhancing probiotic agent, or a methanogenesis-enhancing prebiotic agent.
Methods Of Diagnosing And Treating Small Intestinal Bacterial Overgrowth (Sibo) And Sibo-Related Conditions
US Patent:
8388935, Mar 5, 2013
Filed:
Dec 9, 2011
Appl. No.:
13/315671
Inventors:
Henry C. Lin - Albuquerque NM, US
Mark Pimentel - Los Angeles CA, US
Mark Pimentel - Los Angeles CA, US
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
International Classification:
A61K 49/00, A61K 35/00, A61K 45/00
US Classification:
424 92, 424 91, 424116, 4242781, 424439, 426 5, 426 71, 426658, 426800, 435 5, 435 29
Abstract:
Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed.
Methods Of Treating A Subject Suffering From Irritable Bowel Syndrome
US Patent:
7718608, May 18, 2010
Filed:
Sep 19, 2008
Appl. No.:
12/234502
Inventors:
Henry C Lin - Manhattan Beach CA, US
Mark Pimentel - Los Angeles CA, US
Mark Pimentel - Los Angeles CA, US
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
International Classification:
A01N 37/18, A61K 39/00
US Classification:
514 2, 4241841
Abstract:
Disclosed are methods of treating a subject suffering from irritable bowel syndrome which involves administering rifaximin to the subject and reducing the symptoms of irritable bowel syndrome. Also disclosed are methods of improving the symptoms in a subject caused by irritable bowel syndrome.
Use Of Glp-1 Receptor Agonists For The Treatment Of Short Bowel Syndrome
US Patent:
8236760, Aug 7, 2012
Filed:
Apr 24, 2008
Appl. No.:
12/597892
Inventors:
Mark Pimentel - Los Angeles CA, US
Edy E. Soffer - Los Angeles CA, US
Jeffrey Conklin - Los Angeles CA, US
Edy E. Soffer - Los Angeles CA, US
Jeffrey Conklin - Los Angeles CA, US
Assignee:
Cedars-Sinsai Medical Center - Los Angeles CA
International Classification:
A61K 38/26, A61K 38/00
US Classification:
514 72, 514 117, 530300
Abstract:
The present invention describes the methods of using incretin mimetics such as GLP-1 receptor agonists, particularly exenatide, to treat short bowel syndrome and spastic or hyperactive esophageal motor disorders.